Literature DB >> 11431328

Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells.

G Jones1, J Machado, A Merlo.   

Abstract

In glioblastoma cells, inhibition of focal adhesion kinase (FAK) by the focal adhesion targeting domain attenuated epidermal growth factor receptor (EGFR) signaling, inhibiting epidermal growth factor-dependent migration. Although the EGFR-specific antagonist PD153035 increased caspase-3 activity, this was independent of FAK activity. Instead, the increase in apoptosis upon inhibition of FAK induced the aggregation of an NH(2)-terminal FAK fragment normally present in the nucleus. A recombinant NH(2)-terminal FAK construct was also targeted to the nucleus and aggregated in apoptotic cells upon coexpression with the focal adhesion targeting domain. Therefore, loss of FAK from the focal adhesions inhibits EGFR signaling at the cell membrane and transmits a proapoptotic signal to an NH(2)-terminal variant of FAK present in the nucleus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431328

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Upregulation of CPNE3 suppresses invasion, migration and proliferation of glioblastoma cells through FAK pathway inactivation.

Authors:  Dijian Shi; Bo Lin; Jun Lai; Kaipeng Li; Yimo Feng
Journal:  J Mol Histol       Date:  2021-03-16       Impact factor: 2.611

2.  Role of focal adhesion kinase (FAK) in renal ischaemia and reperfusion.

Authors:  Konstantin Holzapfel; Wolfgang Neuhofer; Helmut Bartels; Maria-Luisa Fraek; Franz-Xaver Beck
Journal:  Pflugers Arch       Date:  2007-06-05       Impact factor: 3.657

3.  Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.

Authors:  Katrin Liffers; Katarina Kolbe; Manfred Westphal; Katrin Lamszus; Alexander Schulte
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

4.  In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation.

Authors:  Markus J Riemenschneider; Wolf Mueller; Rebecca A Betensky; Gayatry Mohapatra; David N Louis
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

5.  Inhibition of focal adhesion kinase induces apoptosis in human osteosarcoma SAOS-2 cells.

Authors:  Jialiang Wang; Jianing Zu; Gongping Xu; Wei Zhao; Yan Jinglong
Journal:  Tumour Biol       Date:  2013-10-04

6.  Inhibition of focal adhesion kinase induces apoptosis in human gastric carcinoma cells (SGC-7901).

Authors:  Jiyou Li; Qingfeng Meng; Yu Sun; Huadong Qing
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

Review 7.  FERM control of FAK function: implications for cancer therapy.

Authors:  Ssang-Taek Lim; David Mikolon; Dwayne G Stupack; David D Schlaepfer
Journal:  Cell Cycle       Date:  2008-05-29       Impact factor: 4.534

Review 8.  Genes and pathways driving glioblastomas in humans and murine disease models.

Authors:  Adrian Merlo
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

9.  MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells.

Authors:  Sarmistha Talukdar; Anjan K Pradhan; Praveen Bhoopathi; Xue-Ning Shen; Laura A August; Jolene J Windle; Devanand Sarkar; Frank B Furnari; Webster K Cavenee; Swadesh K Das; Luni Emdad; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-14       Impact factor: 11.205

10.  Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.

Authors:  Alexander Schulte; Katrin Liffers; Annegret Kathagen; Sabine Riethdorf; Svenja Zapf; Adrian Merlo; Katharina Kolbe; Manfred Westphal; Katrin Lamszus
Journal:  Neuro Oncol       Date:  2013-07-21       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.